Inability of speculation to explain dose effect differences between botulinum toxin products

Archives of Facial Plastic Surgery

Volumn 14, Issue 6, 2012, Pages 467-468

  Pickett, Andy ^a,b  

^a Toxin Science Limited   (United Kingdom)

^b Botulinum Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CUTANEOUS PARAMETERS; DRUG EFFECT; ESTHETIC SURGERY; FEMALE; HUMAN; LETTER; MALE;

BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 84872112616     PISSN: 15212491     EISSN: 15383660     Source Type: Journal    
DOI: 10.1001/jamafacial.2013.366     Document Type: Letter

References (14)

1. Yu KC, Nettar KD, Bapna S, Boscardin WJ, Maas CS. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2012;14(3):198-204.
2. Nettar KD, Yu KC, Bapna S, Boscardin J, Maas CS. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011;13(6):380-386.
3. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87(11):719.
4. Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet. 1994;344(8920):474-475.
5. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, doseranging study. Dermatol Surg. 2009;35(10):1478-1486.
6. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007;33(1, theme issue.):S51-S59.
7. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;59(1):102-103.
8. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment Curr Med Res Opin. 2009;25(7):1573-1584.
9. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35(1):1-8.
10. Dysport prescribing information. http://pi.medicis.us/printer-friendly/ dysport .pdf. Accessed February 1, 2012.
11. Botox Cosmetic prescribing information. http://www.allergan.com/assets/ pdf/botox-cosmetic-pi.pdf. Accessed February 1, 2012.
12. International Neuromodulation Society. Neuromodulation therapies. http://www.neuromodulation.com/treatment. Accessed January 11, 2012.
13. North American Neuromodulation Society. About neuromodulation. http://www.neuromodulation.org/About-Neuromodulation/About -Neuromodulation/ aboutneuromodulation.html. Accessed January 11, 2012.
14. Eisele K-H, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57(4):555-565.